RecruitingNot ApplicableNCT05224934

Preoperative Ultra-hypofractionated Radiotherapy Followed by Surgery for Retroperitoneal Sarcoma (FUSION-01)

Full-target Ultra-hypofractionated Stereotactic Irradiation Orchestrated With Nodule Boost for Retroperitoneal Sarcoma


Sponsor

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Enrollment

50 participants

Start Date

Jan 1, 2022

Study Type

INTERVENTIONAL

Conditions

Summary

To investigate the feasibility and peri-operative complications of preoperative hypo-fractionated radiotherapy followed by surgery for retroperitoneal sarcoma


Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This trial is investigating whether giving a short, concentrated course of radiation before surgery (called ultra-hypofractionated radiotherapy) is a safe and effective treatment for retroperitoneal sarcoma — a rare soft tissue cancer found deep in the abdomen. **You may be eligible if...** - You have a primary soft tissue sarcoma located in the retroperitoneal space (deep abdomen) or pelvic area - Your cancer did not originate from bone, abdominal organs, or gynecological organs - All of your tumor can be safely included in a single radiation field - You are fit for surgery following radiation **You may NOT be eligible if...** - Your cancer has spread to distant sites (metastatic disease) - Your tumor extends through the sciatic notch or certain sensitive areas where radiation is unsafe - You have received prior radiation to the treatment area - You have certain connective tissue diseases that increase radiation sensitivity Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

RADIATIONultra-hypofractionated radiotherapy

stereotactic ablative radiotherapy with 25 to 50Gy in five fractions given preoperatively


Locations(1)

Radiotherapy Department of Cancer Hospital, Chinese Academy of Medical Sciences

Beijing, Beijing Municipality, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05224934


Related Trials